BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barreto TL, Rossato L, de Freitas ALD, Meis JF, Lopes LB, Colombo AL, Ishida K. Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris. Int J Antimicrob Agents 2020;56:106049. [PMID: 32544569 DOI: 10.1016/j.ijantimicag.2020.106049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Bergin SA, Zhao F, Ryan AP, Müller CA, Nieduszynski CA, Zhai B, Rolling T, Hohl TM, Morio F, Scully J, Wolfe KH, Butler G. Systematic Analysis of Copy Number Variations in the Pathogenic Yeast Candida parapsilosis Identifies a Gene Amplification in RTA3 That is Associated with Drug Resistance. mBio 2022;:e0177722. [PMID: 36121151 DOI: 10.1128/mbio.01777-22] [Reference Citation Analysis]
2 Alonso L, Rocha OB, de Carvalho Junior MAB, Soares CMA, Pereira M, Alonso A. Paracoccidioides brasiliensis plasma membrane characterization by EPR spectroscopy and interactions with amphotericin B, miltefosine and nerolidol. J Biomol Struct Dyn 2022;:1-11. [PMID: 35787240 DOI: 10.1080/07391102.2022.2093274] [Reference Citation Analysis]
3 Hoenigl M, Sprute R, Arastehfar A, Perfect JR, Lass-Flörl C, Bellmann R, Prattes J, Thompson GR 3rd, Wiederhold NP, Al Obaidi MM, Willinger B, Arendrup MC, Koehler P, Oliverio M, Egger M, Schwartz IS, Cornely OA, Pappas PG, Krause R. Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs 2022. [PMID: 35657026 DOI: 10.1080/13543784.2022.2086120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 de Moraes DC. Current scenario of the search for new antifungal agents to treat Candida auris infections: An integrative review. J Mycol Med 2021;32:101232. [PMID: 34883404 DOI: 10.1016/j.mycmed.2021.101232] [Reference Citation Analysis]
5 Barreto TL, Lopes LB, Melo AS, Ishida K. In vivo synergism of free miltefosine or in alginate-based nanocarrier combined with voriconazole on aspergillosis. Future Microbiol 2021;16:1153-60. [PMID: 34615383 DOI: 10.2217/fmb-2021-0056] [Reference Citation Analysis]
6 Dos Reis TF, Horta MAC, Colabardini AC, Fernandes CM, Silva LP, Bastos RW, Fonseca MVL, Wang F, Martins C, Rodrigues ML, Silva Pereira C, Del Poeta M, Wong KH, Goldman GH. Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine. mBio 2021;12:e0145821. [PMID: 34372704 DOI: 10.1128/mBio.01458-21] [Reference Citation Analysis]
7 Giacobbe DR, Magnasco L, Sepulcri C, Mikulska M, Koehler P, Cornely OA, Bassetti M. Recent advances and future perspectives in the pharmacological treatment of Candida auris infections. Expert Rev Clin Pharmacol 2021;:1-16. [PMID: 34176393 DOI: 10.1080/17512433.2021.1949285] [Reference Citation Analysis]
8 Aghaei Gharehbolagh S, Izadi A, Talebi M, Sadeghi F, Zarrinnia A, Zarei F, Darmiani K, Borman AM, Mahmoudi S. New weapons to fight a new enemy: A systematic review of drug combinations against the drug-resistant fungus Candida auris. Mycoses 2021. [PMID: 33774879 DOI: 10.1111/myc.13277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Billamboz M, Fatima Z, Hameed S, Jawhara S. Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris. Microorganisms 2021;9:634. [PMID: 33803604 DOI: 10.3390/microorganisms9030634] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
10 Heard SC, Wu G, Winter JM. Antifungal natural products. Curr Opin Biotechnol 2021;69:232-41. [PMID: 33640596 DOI: 10.1016/j.copbio.2021.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kovács R, Nagy F, Tóth Z, Forgács L, Tóth L, Váradi G, Tóth GK, Vadászi K, Borman AM, Majoros L, Galgóczy L. The Neosartorya fischeri Antifungal Protein 2 (NFAP2): A New Potential Weapon against Multidrug-Resistant Candida auris Biofilms. Int J Mol Sci 2021;22:E771. [PMID: 33466640 DOI: 10.3390/ijms22020771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
12 Rossato L, Camargo Dos Santos M, Vitale RG, de Hoog S, Ishida K. Alternative treatment of fungal infections: Synergy with non-antifungal agents. Mycoses 2021;64:232-44. [PMID: 33098146 DOI: 10.1111/myc.13203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Frías-De-León MG, Hernández-Castro R, Vite-Garín T, Arenas R, Bonifaz A, Castañón-Olivares L, Acosta-Altamirano G, Martínez-Herrera E. Antifungal Resistance in Candida auris: Molecular Determinants. Antibiotics (Basel) 2020;9:E568. [PMID: 32887362 DOI: 10.3390/antibiotics9090568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]